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stress echocardiography study, patients with enlarged left atrium
have 3.4 times the event rate of a normal LA size (0.5%/year vs.
1.7%/year). This might not merit further invasive workup. How-
ever, it does merit aggressive medical management of risk factors,
because an event rate of 1.7%/year cannot be considered as benign
as the same event rate in a mildly abnormal stress echocardiogra-
phy study (wall motion score index 1.1 to 1.7) (12). Thus, we
disagree with Dr. Farzaneh-Far and colleagues that LA size should
not be incorporated into risk stratification. In echocardiography as
in other imaging techniques, evaluating multiple parameters de-
fines diagnostic and prognostic data more accurately. As stated in
our article, “further studies using LA volumes are needed to
elucidate the role of diastolic dysfunction in patients undergoing
stress echocardiography and to further evolve the concept of
diastolic stress echocardiography.”
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A Need to Pause and Reflect
The recent State-of-the-Art Paper by Bangalore et al. (1) ques-
tioned the utility of betablockers as first-line treatment for “un-
complicated” hypertension. Although the authors indicate that
they “do not want to throw the baby out with the bathwater,” we
are concerned that the overall tone of the article is so negative that
this indeed might happen. Thus, we believe that the following
comments might be helpful when clinicians are deciding whether
or not to use beta-blockers in a particular patient.
Bangalore et al. (1) cited a lack of benefit with beta-blockers in
reducing all-cause or cardiovascular mortality and myocardial
infarction from a meta-analysis by Lindholm et al. (2); in fact, no
difference was observed for these end points versus other anti-
hypertensives. Some of the early assessments of beta-blockers,
including the STOP-1 and -2 (Swedish Trial in Old Patients with
Hypertension-1 and -2), showed that beta-blockers reduced total
and cardiovascular morbidity compared with placebo and that the
results were similar to angiotensin-converting enzyme (ACE)
inhibitors and calcium channel blockers (3,4).
Most of the evidence summarized by Bangalore et al. (1)
concern studies of atenolol. However, the authors neglected to
point out that the less favorable clinical outcomes seen with
atenolol versus other therapies might be due to an absence of 24-h
efficacy when it is used once daily at a dose of 50 mg. In fact, the
INVEST (International Verapamil-Trandolapril Study) demon-
strated no difference in outcomes between a beta-blocker– and
calcium-antagonist–based regimen (5). Notably, in this trial
atenolol was dosed twice daily. Similarly, data from the UKPDS
(United Kingdom Prospective Diabetes Study) also showed ateno-
lol to have efficacy similar to an ACE inhibitor regimen in
preventing macrovascular complications in hypertensive diabetic
patients (6).
We also believe that the term, “pseudo antihypertensive” effi-
cacy, is misleading, because the authors probably refer to relative
blood pressure reductions as distinct from the efficacy of treating
the disease, hypertension. As the authors point out, beta-blockers
are important for treating a wide range of high-risk cardiovascular
conditions.
We agree with the authors that, historically, use of traditional
beta-blockers has been constrained by associated side effects, in
particular, fatigue and sexual dysfunction. However, there is
mounting evidence showing that the side effect profile of vasodi-
latory beta-blockers is markedly different and comparable to
placebo (7,8). Vasodilating beta-blockers also demonstrate neutral
or beneficial metabolic profiles. As cited by the authors, the
GEMINI (Glycemic Effects in Diabetes Mellitus: Carvedilol-
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Metoprolol Comparison in Hypertensives) study in diabetic hy-
pertensives showed maintained glycemic control and improved
insulin resistance with carvedilol versus metoprolol (8). Similarly,
nebivolol demonstrated improved insulin sensitivity when com-
pared with metoprolol in hypertensive patients (9).
The authors incorrectly state that the European Society for
Hypertension/European Society of Cardiology (ESH/ESC) is
no longer endorsing beta-blockers as first-line therapy for
hypertension. In actuality, ESH/ESC guidelines, published this
year, maintain beta-blockers among the classes of drugs suitable
for initiation and maintenance of blood pressure treatment (10).
Furthermore, ESH/ESC and the American College of Clinical
Endocrinologists recognize the differences that exist between
agents in this class, distinguishing the vasodilatory beta-
blockers from traditional ones in patients with metabolic risk
factors.
We are not sure what the phenotype of an “uncomplicated”
patient with hypertension is. Clearly, many with increased blood
pressures have non-obstructive coronary and carotid plaques.
The use of beta-blockers in the treatment of patients with
hypertension is deeply rooted in the knowledge of the role of the
sympathetic nervous system in the pathophysiology of complica-
tions. We believe that recommendations for the use of beta-
blockers in an individual with hypertension should be made after
reviewing the totality of the data. Beta-blockers will continue to
play a critical role in treatment of hypertension, and dismissing the
entire class without fully examining the evidence might indeed
amount to “throwing the baby out with the bath water.”
Thomas D. Giles, MD*
George L. Bakris
Michael A. Weber
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Reply
We thank Dr. Giles and colleagues for their interest in our paper
(1) and completely agree with their contention that “recommen-
dations for the use of beta-blockers in the individual with hyper-
tension should be made after reviewing the totality of the data.”
Unfortunately, the totality in this case is completely negative. Ever
since our meta-analysis about a decade ago, study after study has
attested to the inefficacy of beta-blockers in hypertension. Why
would any physician expose a hypertensive patient to a drug that
reduces mortality no better than placebo, as evidenced in the
thorough Cochrane meta-analysis (2), and yet leads to a with-
drawal rate that is twice as high as the one seen with diuretics
(which are certainly not the best-tolerated drug class for the
treatment of hypertension)? We are puzzled by our colleagues’
cherrypicking of the STOP-1 and -2 (Swedish Trial in Old
Patients with Hypertension-1 and -2). Neither of those studies
dared to conclude that beta-blockers per se reduce morbidity and
mortality. The reason for this is very simply that neither one
analyzed the effects of diuretics and beta-blockers separately. Thus,
STOP-1 and -2 studies are classical examples of gin-and-tonic
studies in which about two-thirds of patients treated with a
beta-blocker also received a thiazide diuretic.
The INVEST (International Verapamil-Trandolapril Study) is
a landmark trial in which an atenolol (given mostly twice a
day)-based regimen was compared with a verapamil-based regi-
men, as Dr. Giles and colleagues point out. However, all of the
patients in the INVEST study had well defined coronary artery
disease, and an extrapolation from such a high-risk population to
uncomplicated hypertension is not appropriate. As can be seen in
our Figure 3 (1) we are convinced that coronary artery disease is an
acceptable indication for the use of beta-blockers.
We use the term pseudoantihypertensive efficacy to describe the
observation in the CAFE (Conduit Artery Function Evaluation)
study (3) that, for a given brachial blood pressure, atenolol lowered
central aortic blood pressure significantly less than did amlodipine.
Therefore, practicing physicians may wrongly conclude that the
patient has well controlled hypertension when central aortic
pressure is still significantly elevated. The term pseudoantihyper-
tensive efficacy aptly describes this phenomenon.
We certainly agree with our colleagues, and we have stated so
(4), that vasodilating beta-blockers have a different hemodynamic
profile and a different metabolic/endocrine profile, induce less
weight gain (5), and are better tolerated than the traditional
beta-blockers. Thus, nebivolol and carvedilol are not only better
tolerated but also have the potential to be more beneficial in terms
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